Theseus Pharmaceuticals is engaged in the discovery, development and commercialization of targeted therapies for cancer patients. Co.'s development programs are designed to address drug resistance mutations in key driver oncogenes. Co.'s product candidate, THE-630, is a pan-variant inhibitor of all main classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumours. Co.'s second program is focused on inhibitors of epidermal growth factor receptor (EGFR), that are active against C797S, the common EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. We show 4 historical shares outstanding datapoints in our THRX shares outstanding history coverage, used to compute THRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing THRX market cap history over the course of time is important for investors
interested in comparing THRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of THRX versus a peer is one thing; comparing
THRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like THRX can fluctuate over the course of history.
With this page we aim to empower investors researching THRX by allowing them to research the THRX market cap history. |
Free THRX Email Alerts:
Video: The Importance of Market Cap
